
UK pricing watchdog NICE has performed a U-turn on Glivec (imatinib) by issuing new draft guidance recommending the drug, despite …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

